Genetically modified NK cells take on rare sarcomas in early trial
NCT ID NCT06083883
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new therapy for people with advanced synovial sarcoma or myxoid/round cell liposarcoma. Participants receive donated natural killer (NK) cells that have been engineered to recognize and attack a protein called NY-ESO-1 found on their cancer cells. These cells are given alongside two chemotherapy drugs to help them work better. The study aims to find the safest dose and check for side effects in 44 patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
engineered natural killer (NK) cells that target the NY-ESO-1 protein, given with chemotherapy drugs fludarabine and cyclophosphamide
What this could lead to
If successful, this could point toward a new treatment option for people with advanced synovial sarcoma or liposarcoma that has not responded to other therapies.
What could go wrong
This is a very early (Phase 1) trial with only 44 participants, so the main goal is safety, not effectiveness. The treatment may not shrink tumors or could cause serious side effects from the chemotherapy or the cell infusion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYNOVIAL SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact